Back
Gyre Therapeutics, Inc. 10K Form
Sell
34
GYRE
Gyre Therapeutics, Inc.
Last Price:
$7.14
Seasonality Move:
-0.78%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive GYRE News And Ratings
See the #1 stock for the next 7 days that we like better than GYRE
GYRE Financial Statistics
Sales & Book Value
| Annual Sales: | $116.6M |
|---|---|
| Cash Flow: | $-5.8M |
| Price / Cash Flow: | 528.63 |
| Annual Sales: | $1.16 |
| Price / Book: | 6.06 |
Profitability
| EPS (TTM): | 0.02250 |
|---|---|
| Net Income (TTM): | $9.9M |
| Gross Margin: | $111.2M |
| Return on Equity: | 8.07% |
| Return on Assets: | 6.74% |
Gyre Therapeutics, Inc. Earnings Forecast
Key Gyre Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 24 years for GYRE is 95.35%.
-
The Selling, General & Administrative Expenses for GYRE have been equal to 73.75% of Gross Profit Margin.
-
The Research & Development expenses have been 11.75% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of GYRE is 8.47% of Total Revenues.
-
Per Share Earnings over the last 24 years have been positive in 13 years.
Gyre Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | GYRE |
| Website: | gyretx.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 5.6 |
| Quick Ratio: | 4.88 |
Price-to-Earnings
| Trailing P/E Ratio: | 312.51 |
|---|---|
| Forward P/E Ratio: | 125.92 |
GYRE Technical Analysis vs Fundamental Analysis
Sell
34
Gyre Therapeutics, Inc. (GYRE)
is a Sell
Is Gyre Therapeutics, Inc. a Buy or a Sell?
-
Gyre Therapeutics, Inc. stock is rated a SellThe current Gyre Therapeutics, Inc. [GYRE] share price is $7.12. The Score for GYRE is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.